What is he best known for?
The fields of study he is best known for:
- Gene
- Immune system
- Antibody
Jörg Köhl mainly investigates Immunology, Immune system, C5a receptor, Receptor and Anaphylatoxin.
His Immunology research focuses on Proinflammatory cytokine, Inflammation, Acquired immune system, Complement C5a and Complement system.
Jörg Köhl works mostly in the field of Immune system, limiting it down to topics relating to Crosstalk and, in certain cases, Notch Family, Notch proteins, Notch signaling pathway, Interleukin 10 and Jagged-1 Protein.
In his study, which falls under the umbrella issue of C5a receptor, Quantitative trait locus, Gene, Cancer research, Apoptosis and Kidney is strongly linked to Complement factor I.
His Receptor study combines topics in areas such as Pharmacology and Transplantation.
His Anaphylatoxin research is multidisciplinary, incorporating perspectives in Allergen, Cell biology, Immunopathology and Monocyte.
His most cited work include:
- The role of the anaphylatoxins in health and disease. (449 citations)
- The role of the anaphylatoxins in health and disease. (449 citations)
- Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation (381 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Immunology, Immune system, Complement system, C5a receptor and Cell biology.
Much of his study explores Immunology relationship to Receptor.
His study in Immune system is interdisciplinary in nature, drawing from both Antibody and Cytokine.
The concepts of his Complement system study are interwoven with issues in Sepsis and Effector.
His C5a receptor research incorporates elements of Glucocerebrosidase and Complement C5a, Chemotaxis.
His studies in Cell biology integrate themes in fields like Secretion and Monocyte.
He most often published in these fields:
- Immunology (85.97%)
- Immune system (47.16%)
- Complement system (40.30%)
What were the highlights of his more recent work (between 2017-2021)?
- Immunology (85.97%)
- Complement system (40.30%)
- Immune system (47.16%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Immunology, Complement system, Immune system, Innate immune system and C5a receptor.
His Immunology study is mostly concerned with Inflammation, Autoantibody, Epidermolysis bullosa acquisita, Antibody and Asthma.
Jörg Köhl interconnects Complement, Cancer research and Sepsis in the investigation of issues within Complement system.
His Immune system study combines topics from a wide range of disciplines, such as Interleukin 33, Interleukin, Airborne allergen and Lung.
His study looks at the intersection of Innate immune system and topics like Effector with Receptor, Lectin pathway, Pathogenesis and Thrombotic microangiopathy.
Jörg Köhl focuses mostly in the field of C5a receptor, narrowing it down to topics relating to Alternative complement pathway and, in certain cases, Glucocerebrosidase.
Between 2017 and 2021, his most popular works were:
- Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. (28 citations)
- Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. (28 citations)
- Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2. (21 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Immune system
- Antibody
Jörg Köhl focuses on Complement system, Immune system, Immunology, Innate immune system and C5a receptor.
His Complement system research includes elements of Non canonical and Complement.
His Immunology study frequently intersects with other fields, such as In vitro.
Jörg Köhl usually deals with Innate immune system and limits it to topics linked to Effector and Lectin pathway, Anaphylatoxin, Pathogenesis and Thrombotic microangiopathy.
His biological study spans a wide range of topics, including Alternative complement pathway, Epidermolysis bullosa acquisita, Complement factor B and Eculizumab.
His Alternative complement pathway study incorporates themes from Glucocerebrosidase, Receptor, Complement membrane attack complex and Cell biology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
